Other CDK9 or pan-CDK inhibitors are in developmental stage, such as LS-007/CDKI-73 [180], LY2857785 [181] or, more recently, JSH-150, which inhibited CDK9 at the nM range and showed interesting anti-leukemic effects in mice inoculated with the MV4-11 human AML-AF4 MPAL model [182]. Here, CDK9 is linked to acute myeloid leukemia.